Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Collagen type VI alpha 1 chain (COL6A1) encodes the α1 subunit of collagen VI, an essential extracellular matrix protein that assembles into a microfibrillar network to maintain tissue structural integrity and regulate cell–matrix interactions. Type VI collagen is especially important in skeletal muscle, cartilage, tendon, bone, and basement membranes, where it provides mechanical support, links basement membranes to cells, and contributes to cytoprotective pathways (modulating apoptosis, autophagy, and stem cell renewal). Defects in COL6A1 cause a spectrum of muscle and connective tissue diseases, most prominently Bethlem myopathy and Ullrich congenital muscular dystrophy, by disrupting microfibril assembly and cell–matrix signaling. COL6A1 serves as a diagnostic marker for certain myopathies and is under investigation as a therapeutic target and biomarker for tissue engineering and regenerative medicine.
Potential drugs may act by regulating autophagy or stabilizing extracellular matrix interactions. Modulation of apoptotic and mechanotransductive signaling in muscle fibers.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Collagen type VI alpha 1 chain (COL6A1).